<img alt="" src="https://secure.agile-company-247.com/261975.png" style="display:none;">

Medtech & Healthtech stage


Designed exclusively for medtech & healthtech companies.

 

10:30

Medtech Investment Dynamics - Pragmatic advice and optimism for 2023?

With a record-breaking benchmark set in 2021, are the slowing IPOs, M&As and a muted performance in SPACs an accurate portrayal of a seemingly quieter MedTech market? A panel of MedTech investors discuss how the current landscape will inform investment in 2023 and how MedTech companies can prepare for the year ahead.

  • How are macro factors (geopolitics, ESG, supply chain, inflation) influencing investment decisions, what does this mean for MedTech companies?
  • Are timelines for securing investment lengthening and, if so, why? How does this differ between early and late-stage funding, across Europe and the US?
  • With money becoming less of a commodity, what markets and device types are receiving attention from investors and how can companies build robust pitches to attract investment?

Joachim Rautter, Managing Partner, Peppermint Venture Partners
Rebecca Todd
, Investment Director, Longwall Venture Partners
Lior Teitelbaum
, Senior Director, Venture Investments, Johnson & Johnson Innovation
Vivien de Tusch-Lec
, General Partner, RYSE Asset Management

Joachim Rautter, Managing Partner, Peppermint Venture Partners GmbH 300xRebecca Todd, Investment Director, Longwall Venture PartnersLior Teitelbaum, Senior Director, Venture Investments, Johnson & Johnson InnovationVivien de Tusch-Lec, General Partner, RYSE Asset Management


11:15 Locate Bio Logo

 


11:30 Radiance Therapeutics Logo

 


11:45 Biofidelity Logo

 


12:00 Numan Logo

 


12:15 ARC Medical Logo

 


12:30 Pixium Vision Logo

 


12:45 CeiROx Life Sciences Logo

 


13:00 Oxford Endovascular Logo

 


13:15 Harmonic Bionics Logo

 


13:30 Affluent Medical Logo

 


13:45 miDiagnostics 300x

 


14:00

Investment within Digital Health & Healthtech: Reviewing the success, growth and funding

  • Evaluating the year so far- How does early-stage investment compare to late-stage investment?
  • Have the regulatory advancements in Europe affected investment activity in the digital therapeutics and digital health space?
  • How do we make Europe a destination of choice for VC Start-up scale up?
  • Contrasting US and EU investment landscapes: Looking at the differences, US have higher valuations, raise a lot more capital. Why is that?
  • Are we now beyond the hype? The adoption of AI and machine learning in healthcare

Catherine Boule, Managing Partner, Karista
Rabab Nasrallah, Investment Associate, Earlybird Health
Vijay Barathan
, Partner, Optum Ventures
Guillem Masferrer
, Investment Director, Asabys

Catherine Boule, Managing Partner, KaristaRabab Nasrallah, Investment Associate, Earlybird HealthVijay Barathan, Senior Principal, Optum Ventures 300xGuillem Masferrer, Investment Director, Asabys


14:45

Hy2care 300x

 


15:00

Cutiss AG Logo

 


15:15

InfanDx AG Logo

 


15:30

Curesponse Logo

 


15:45

TechnoPulm Logo

 


16:00 Genetika+ Logo

 


16:15

Genefirst Logo

 


16:30

Butterfly Medical Logo

 


16:45

Kinetikos Health Logo

 


17:00

ImageBiopsyLab Logo

 


17:15

Close of Investival Showcase


18:30

Lifestars Logo

Awards & Gala Dinner
- Separate ticket required
- Find out more

DOWNLOAD BROCHURE